Answers are grounded in this paper and cite their sources.
The development of small-molecule inhibitors of the epidermal growth factor receptor (EGFR), such as erlotinib and gefitinib, for the treatment of advanced non–small-cell lung cancer illustrates a pattern of initial overly enthusiastic interest, subsequent critical disappointment, and eventual renewed appreciation of the clinical and mechanistic complexities surrounding the introduction of a new therapy for cancer. Such a pattern has been regrettably common in the history of oncologic therapeutics.The initial safety and efficacy studies of erlotinib and gefitinib evoked a remarkable degree of optimism that was based on prolonged remissions and, in some cases, dramatic improvements in the quality of . . .
No takes yet. Share an insight, caveat, or question.
James H. Doroshow (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: